Focal Segmental Glomerulosclerosis (FSGS) Completed Phase 2 Trials for Irbesartan (DB01029)

Also known as: Focal Glomerulosclerosis / Glomerulosclerosis, Focal / Focal Segmental Glomerulosclerosis / Glomerulosclerosis, Focal Segmental / APOL1-mediated focal segmental glomerulosclerosis / Focal & segmental glomerulosclerosis / Focal glomerular sclerosis (disorder) / Focal segmental glomerulosclerosis (disorder)

IndicationStatusPhase
DBCOND0038485 (Focal Segmental Glomerulosclerosis (FSGS))Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01613118Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental GlomerulosclerosisTreatment